Pharmacokinetic Modeling of Therapies for Systemic Lupus Erythematosus

Overview

Journal Expert Rev Clin Pharmacol

Specialty Pharmacology

Date 2015 Jul 7

PMID 26143647

Citations 2

Authors

Xiaoyan Yang

Catherine M T Sherwin

Tian Yu

Venkata K Yellepeddi

Hermine I Brunner

Alexander A Vinks

Affiliations

Soon will be listed here.

Abstract

With the increasing use of different types of therapies in treating autoimmune diseases such as systemic lupus erythematosus (SLE), there is a need to utilize pharmacokinetic (PK) strategies to optimize the clinical outcome of these treatments. Various PK analysis approaches, including population PK modeling and physiologically based PK modeling, have been used to evaluate drug PK characteristics and population variability or to predict drug PK profiles in a mechanistic manner. This review outlines the PK modeling of major SLE therapies including immunosuppressants (methotrexate, azathioprine, mycophenolate and cyclophosphamide, among others) and immunomodulators (intravenous immunoglobulin). It summarizes the population PK modeling, physiologically based PK modeling and model-based individualized dosing strategies to improve the therapeutic outcomes in SLE patients.

Citing Articles

The Role of Pharmacometrics in Advancing the Therapies for Autoimmune Diseases.

Swierczek A, Batko D, Wyska E Pharmaceutics. 2025; 16(12.

PMID: 39771538 PMC: 11676367. DOI: 10.3390/pharmaceutics16121559.

Efficacy and Safety of Pharmacokinetically-Driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis-A Double-Blind Placebo Controlled Clinical Trial (The Pediatric Lupus Nephritis Mycophenolate Mofetil....

Sagcal-Gironella A, Merritt A, Mizuno T, Dharnidharka V, McDonald J, DeGuzman M J Clin Trials. 2024; 14(4).

PMID: 39035447 PMC: 11258879.

Mechanism of Action and Efficacy of Immunosupressors in Lupus Nephritis.

Alamilla-Sanchez M, Alcala-Salgado M, Alonso-Bello C, Fonseca-Gonzalez G Int J Nephrol Renovasc Dis. 2021; 14:441-458.

PMID: 34924767 PMC: 8675090. DOI: 10.2147/IJNRD.S335371.

References

Hochberg M . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9):1725. DOI: 10.1002/art.1780400928. View

Tang Q, Yang Y, Zhao M, Liang G, Wu H, Liu Q . Mycophenolic acid upregulates miR-142-3P/5P and miR-146a in lupus CD4+T cells. Lupus. 2015; 24(9):935-42. DOI: 10.1177/0961203315570685. View

Foran J, Oscier D, Orchard J, Johnson S, Tighe M, Cullen M . Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. J Clin Oncol. 1999; 17(5):1574-9. DOI: 10.1200/JCO.1999.17.5.1574. View

Dervieux T, Furst D, Lein D, Capps R, Smith K, Caldwell J . Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis. 2005; 64(8):1180-5. PMC: 1755602. DOI: 10.1136/ard.2004.033399. View

Vrana A, Andrysek T . The effect of particle size on bioavailability in cyclosporine preparations based on submicron dispersions. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2002; 145(2):9-15. View

Germano V, Picchianti Diamanti A, Ferlito C, Podesta E, Salemi S, Migliore A . Cyclosporine A in the long-term management of systemic lupus erythematosus. J Biol Regul Homeost Agents. 2011; 25(3):397-403. View

Fukuda T, Brunner H, Sagcal-Gironella A, Vinks A . Nonsteroidal anti-inflammatory drugs may reduce enterohepatic recirculation of mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. Ther Drug Monit. 2011; 33(5):658-62. PMC: 4090025. DOI: 10.1097/FTD.0b013e318228195f. View

Yoshidome K, Takei S, Imanaka H, Maeno N, Ohkawa T, Kawano Y . Efficacy of mizoribine in the treatment of systemic lupus erythematosus in children. Pediatr Int. 2004; 46(4):444-9. DOI: 10.1111/j.1442-200x.2004.01923.x. View

Gillespie W . Noncompartmental versus compartmental modelling in clinical pharmacokinetics. Clin Pharmacokinet. 1991; 20(4):253-62. DOI: 10.2165/00003088-199120040-00001. View

10.

Neely M, Jelliffe R . Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization. J Clin Pharmacol. 2008; 48(9):1081-91. PMC: 2724306. DOI: 10.1177/0091270008321789. View

11.

Nozu K, Iijima K, Kamioka I, Fujita T, Yoshiya K, Tanaka R . High-dose mizoribine treatment for adolescents with systemic lupus erythematosus. Pediatr Int. 2006; 48(2):152-7. DOI: 10.1111/j.1442-200X.2006.02178.x. View

12.

Carneiro J, Sato E . Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1999; 26(6):1275-9. View

13.

Kawasaki Y . Mizoribine: a new approach in the treatment of renal disease. Clin Dev Immunol. 2010; 2009:681482. PMC: 2801010. DOI: 10.1155/2009/681482. View

14.

Woillard J, Bader-Meunier B, Salomon R, Ranchin B, Decramer S, Fischbach M . Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring. Br J Clin Pharmacol. 2014; 78(4):867-76. PMC: 4239980. DOI: 10.1111/bcp.12392. View

15.

Stabile A, Miceli Sopo S, Romanelli V, Pastore M, Pesaresi M . Intravenous immunoglobulin for prophylaxis of neonatal sepsis in premature infants. Arch Dis Child. 1988; 63(4):441-3. PMC: 1778825. DOI: 10.1136/adc.63.4.441. View

16.

Robak E, Robak T . Novel and emerging drugs for systemic lupus erythematosus: mechanism of action and therapeutic activity. Curr Med Chem. 2012; 19(3):438-53. DOI: 10.2174/092986712803414312. View

17.

Filler G, Hansen M, LeBlanc C, Lepage N, Franke D, Mai I . Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children. Pediatr Nephrol. 2003; 18(5):445-9. DOI: 10.1007/s00467-003-1133-1. View

18.

Fu L, Yang L, Chen W, Lin C . Cyclosporin pharmacokinetics following administration of capsules and Neoral in paediatric patients with lupus nephritis. Br J Clin Pharmacol. 1997; 44(2):125-7. PMC: 2042826. DOI: 10.1046/j.1365-2125.1997.00634.x. View

19.

Kyllonen K, Clapp D, Kliegman R, Baley J, Shenker N, Fanaroff A . Dosage of intravenously administered immune globulin and dosing interval required to maintain target levels of immunoglobulin G in low birth weight infants. J Pediatr. 1989; 115(6):1013-6. DOI: 10.1016/s0022-3476(89)80761-9. View

20.

Jang G, Harris R, Lau D . Pharmacokinetics and its role in small molecule drug discovery research. Med Res Rev. 2001; 21(5):382-96. DOI: 10.1002/med.1015. View